Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022 06:30 ET
|
Ayala Pharmaceuticals
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in...
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
September 29, 2022 08:00 ET
|
Ayala Pharmaceuticals
Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102KOLs and management to present on Thursday, October 6th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del.,...
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
September 27, 2022 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
September 12, 2022 08:00 ET
|
Ayala Pharmaceuticals
- Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period - - Consistent early tumor...
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
August 24, 2022 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 16:05 ET
|
Ayala Pharmaceuticals
Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data...
Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors
July 05, 2022 08:00 ET
|
Ayala Pharmaceuticals
- Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed: AL102 was well tolerated - - Additional data to be submitted for...
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
June 06, 2022 08:00 ET
|
Ayala Pharmaceuticals
-- Presentation at ASCO features updated results from Phase 2 ACCURACY study -- -- AL101 demonstrated anti-tumor activity by achieving an overall disease control rate of 69% -- -- Patients achieving...
Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 16:05 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...